Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Oral EPI-506 in Metastatic Castration-Resistant Prostate Cancer
2015-004764-10Phase 2Terminated
- Sponsor
- ESSA Pharma
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ralaniten acetate in prostate cancer (PCa), sponsored by ESSA Pharma. Primary endpoint: Dose-limiting toxicities (DLTs) in Part I. Started Mar 2016; status: terminated.
02
Drugs
ralaniten acetate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-004764-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004764-10.